FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296329001> ?p ?o ?g. }

• W4296329001 abstract "In order to combat the COVID-19 pandemic, an extensive effort is being made by researchers around the world to develop therapeutics against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2). As the name indicates, this virus primarily affects the respiratory tract including lungs. Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. We report that supplementation of octyl-αKG significantly inhibits SARS CoV-2 replication in conjunction with the downmodulation of pAkt-Ser473 and pAkt-Thr308 in the Vero E6 cell line in vitro (Figures 1A–C and S1C) as well as in the human monocytic U937 cell line transiently expressing ACE2(Figures 1D–E, H and S2C), similar to the effect of Akt-inhibitor, triciribine (TCN; Figures 1A–C and S1C). More importantly, octyl-αKG supplementation did not alter the mitochondrial function and ATP release in the cells (Figure S1D). Octyl-αKG decreased ACE2 expression (Figure 1C), potentially by inhibiting pAkt signalling.8 On the other hand, octyl-αKG did not inhibit viral replication (Figures 1F and G and S2D) and pAkt expression (Figure 1J) in PHD2-knockdown U937 cells, thus confirming that the PHD2-pAkt is a target axis of this metabolite. Also we observed an inhibitory effect of octyl-αKG on the other substrates of PHD2, such as HIF1α and HIF2α (Figures 1C and S3I and J). A recent study has described that SARS CoV-2 ORF3 protein induced HIF1α to facilitate viral replication and inflammation in patients.9 However, a further detailed study may explore the role of αKG-PHD2-HIFα axis on SARS CoV-2 replication. Although the enzyme activity of PHD2 was altered after SARS CoV-2 infection and/or after octyl-αKG supplementation, no change in expression of PHD2 protein was observed (Figure 1C). Besides, we also tested the effect of a non-esterified αKG (NE-αKG) on viral replication. Unlike the effect of a lower concentration of octyl-αKG (0.75–1.5 mM,Figures S1C and 1A–C), the NE-αKG showed an inhibitory effect on viral replication alongside downmodulation of pAkt at higher concentrations of 5–7.5 mM (Figure S1E and F). This could be because of low uptake of αKG by Vero cells when treated with NE-αKG compared to octyl-αKG (Figure S9A). Here we show that oral gavage of a dietary grade αKG (40 mg/100 g body wt./day; Figure 2A) till 4 days post-infection of SARS CoV-2 significantly inhibited viral load (Figures 2B and S3C) and downmodulated pAkt (Figures 2I and S3G and H) and HIF2α (Figures 2I and S3I and J) in hamster lungs at 5 days post-infection (dpi). The αKG supplementation till 4 days showed significant inhibitory effect on SARS CoV-2 replication even at 9 dpi (Figure S3). Besides, αKG decreased infection-induced accumulation of inflammatory cells in alveolar spaces (Figure 2C and D) and clot formation in micro vessels (Figure 2E and F), and also reduced apoptotic tissue damage (Figure 2G and H) in the infected lungs. Since, the elevated inflammation/thrombosis/apoptosis is known to cause ARDS and hypoxemia, leading to a decreased SpO2 in the circulation of COVID-19 patients,1, 2 we measured circulating SpO2 in infected animals from the above experiment and observed a significant rescue effect of αKG in restoring normal SpO2 saturation at 4 dpi onwards (Figure 2J). The above experiments in balb/c mice transiently expressing hACE2 also showed a similar result. SARS CoV-2-infected both male (Figure S6 and S7) and female mice (Figure S8). In mice, we could assess some additional parameters showing that the αKG supplementation significantly reduced the elevated counts of leukocytes (Figure S6L and N) and leukocyte-platelet aggregates (Figure S6M and O) along with levels of IL6, TNFα and IL10 in lungs (Figure S6S–U) as well as in plasma (Figure S7A–F) of infected mice. αKG also reduced thrombogenic markers like platelet (CD41a+) microparticles in the circulation of infected mice (Figure S7G and H), suggesting a potent anti-thrombotic role of the metabolite. αKG supplementation improved SpO2 in infected mice as well (Figure S7I). As reported in our recent works,3, 4 we measured an elevated level of αKG in circulating leukocytes as well as in lung tissues of animals after αKG supplementation (Figure S9). We thereafter investigated the effect of αKG on adaptive immune parameters (as described in our recent work10) in hamsters. We observed similar levels of IgG against SARS CoV-2 RBD protein in plasma between infected and infected+αKG groups at 5 dpi (Figure 3A and B) and 9 dpi (Figure 3C and D). We observed a similar efficacy of the plasma-containing antibody from αKG supplemented animals in neutralizing the SARS CoV-2 compared to only the virus-infected group (Figure 3E and F), suggesting no significant interference of this metabolite on antibody response. We also investigated the anti-viral response of T lymphocytes between groups. Dietary αKG did not alter the already elevated percentage of interferon-γ positive (IFNγ+) CD4+ (Figure 3G and I) and IFNγ+CD8+ (Figure 3H and J) T cells in the spleen compared to the virus only at 5 dpi and 9 dpi respectively. The observations raise the possibility that the T-cell response may be blunted following αKG treatment as it inhibits viral replication. Another study has described that αKG supplementation activates Th1 cell function.11 A further detailed investigation may explain the role of αKG on T and B cell responses in SARS CoV-2 infection. However, our data strongly suggest a safe usage of the metabolite without suppressing the anti-viral response of these adaptive immune cells. In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. Therefore, our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19. It may be used alone or in combination with current drugs for the disease. The employment of αKG may open up new avenues of treatment for lung inflammation and thrombosis in other respiratory diseases as well. This study is supported by grants BT/PR22881 and BT/PR22985 from the Department of Biotechnology (DBT), Govt. of India and CRG/000092 from the Science and Engineering Research Board, Govt. of India to PG. Authors thank to Dr. Arundhati Tiwari of Regional Centre for Biotechnology, Faridabad, India, for English editing. The authors declare that they have no competing interests. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4296329001 created "2022-09-20" @default.
• W4296329001 creator A5007732422 @default.
• W4296329001 creator A5022170940 @default.
• W4296329001 creator A5025774887 @default.
• W4296329001 creator A5030196661 @default.
• W4296329001 creator A5034527059 @default.
• W4296329001 creator A5048184940 @default.
• W4296329001 creator A5056599339 @default.
• W4296329001 creator A5058270135 @default.
• W4296329001 creator A5072579760 @default.
• W4296329001 creator A5081204408 @default.
• W4296329001 creator A5089695874 @default.
• W4296329001 creator A5090594256 @default.
• W4296329001 date "2022-09-01" @default.
• W4296329001 modified "2023-10-15" @default.
• W4296329001 title "Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O₂ saturation by inhibiting pAkt" @default.
• W4296329001 cites W2006134086 @default.
• W4296329001 cites W2745378219 @default.
• W4296329001 cites W3027918021 @default.
• W4296329001 cites W3047405892 @default.
• W4296329001 cites W3101668228 @default.
• W4296329001 cites W3166869475 @default.
• W4296329001 cites W3175478564 @default.
• W4296329001 cites W3194203766 @default.
• W4296329001 cites W3210753898 @default.
• W4296329001 cites W3216480419 @default.
• W4296329001 cites W4225716496 @default.
• W4296329001 doi "https://doi.org/10.1002/ctm2.1041" @default.
• W4296329001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36121179" @default.
• W4296329001 hasPublicationYear "2022" @default.
• W4296329001 type Work @default.
• W4296329001 citedByCount "5" @default.
• W4296329001 countsByYear W42963290012022 @default.
• W4296329001 countsByYear W42963290012023 @default.
• W4296329001 crossrefType "journal-article" @default.
• W4296329001 hasAuthorship W4296329001A5007732422 @default.
• W4296329001 hasAuthorship W4296329001A5022170940 @default.
• W4296329001 hasAuthorship W4296329001A5025774887 @default.
• W4296329001 hasAuthorship W4296329001A5030196661 @default.
• W4296329001 hasAuthorship W4296329001A5034527059 @default.
• W4296329001 hasAuthorship W4296329001A5048184940 @default.
• W4296329001 hasAuthorship W4296329001A5056599339 @default.
• W4296329001 hasAuthorship W4296329001A5058270135 @default.
• W4296329001 hasAuthorship W4296329001A5072579760 @default.
• W4296329001 hasAuthorship W4296329001A5081204408 @default.
• W4296329001 hasAuthorship W4296329001A5089695874 @default.
• W4296329001 hasAuthorship W4296329001A5090594256 @default.
• W4296329001 hasBestOaLocation W42963290011 @default.
• W4296329001 hasConcept C114614502 @default.
• W4296329001 hasConcept C116675565 @default.
• W4296329001 hasConcept C126322002 @default.
• W4296329001 hasConcept C141071460 @default.
• W4296329001 hasConcept C159047783 @default.
• W4296329001 hasConcept C181199279 @default.
• W4296329001 hasConcept C185592680 @default.
• W4296329001 hasConcept C2775944032 @default.
• W4296329001 hasConcept C2779134260 @default.
• W4296329001 hasConcept C2910453370 @default.
• W4296329001 hasConcept C3006700255 @default.
• W4296329001 hasConcept C3007834351 @default.
• W4296329001 hasConcept C3008058167 @default.
• W4296329001 hasConcept C33923547 @default.
• W4296329001 hasConcept C49453240 @default.
• W4296329001 hasConcept C524204448 @default.
• W4296329001 hasConcept C55493867 @default.
• W4296329001 hasConcept C64943373 @default.
• W4296329001 hasConcept C71924100 @default.
• W4296329001 hasConcept C9930424 @default.
• W4296329001 hasConceptScore W4296329001C114614502 @default.
• W4296329001 hasConceptScore W4296329001C116675565 @default.
• W4296329001 hasConceptScore W4296329001C126322002 @default.
• W4296329001 hasConceptScore W4296329001C141071460 @default.
• W4296329001 hasConceptScore W4296329001C159047783 @default.
• W4296329001 hasConceptScore W4296329001C181199279 @default.
• W4296329001 hasConceptScore W4296329001C185592680 @default.
• W4296329001 hasConceptScore W4296329001C2775944032 @default.
• W4296329001 hasConceptScore W4296329001C2779134260 @default.
• W4296329001 hasConceptScore W4296329001C2910453370 @default.
• W4296329001 hasConceptScore W4296329001C3006700255 @default.
• W4296329001 hasConceptScore W4296329001C3007834351 @default.
• W4296329001 hasConceptScore W4296329001C3008058167 @default.
• W4296329001 hasConceptScore W4296329001C33923547 @default.
• W4296329001 hasConceptScore W4296329001C49453240 @default.
• W4296329001 hasConceptScore W4296329001C524204448 @default.
• W4296329001 hasConceptScore W4296329001C55493867 @default.
• W4296329001 hasConceptScore W4296329001C64943373 @default.
• W4296329001 hasConceptScore W4296329001C71924100 @default.
• W4296329001 hasConceptScore W4296329001C9930424 @default.
• W4296329001 hasFunder F4320320717 @default.
• W4296329001 hasIssue "9" @default.
• W4296329001 hasLocation W42963290011 @default.
• W4296329001 hasLocation W42963290012 @default.
• W4296329001 hasLocation W42963290013 @default.
• W4296329001 hasOpenAccess W4296329001 @default.
• W4296329001 hasPrimaryLocation W42963290011 @default.
• W4296329001 hasRelatedWork W3009669391 @default.
• W4296329001 hasRelatedWork W3036314732 @default.
• W4296329001 hasRelatedWork W3113664224 @default.
• W4296329001 hasRelatedWork W3176864053 @default.

• next